Master protocol trials in oncology: Review and new trial designs
In oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-12-01
|
Series: | Contemporary Clinical Trials Communications |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865418300565 |
id |
doaj-1fb9d0f5d7ad402d97d9ae65a4070044 |
---|---|
record_format |
Article |
spelling |
doaj-1fb9d0f5d7ad402d97d9ae65a40700442020-11-25T02:32:42ZengElsevierContemporary Clinical Trials Communications2451-86542018-12-011218Master protocol trials in oncology: Review and new trial designsAkihiro Hirakawa0Junichi Asano1Hiroyuki Sato2Satoshi Teramukai3Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8654, Japan; Corresponding author. Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8654, Japan.Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, 100-0013, JapanBiostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, 100-0013, JapanDepartment of Biostatistics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, 602-8566, JapanIn oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that assess the combination of several molecular markers and their targeted therapies by means of multiple sub-studies are required. These protocols are called “master protocols,” and are drawing attention as a next-generation clinical trial design. Recently, several reviews of clinical trials based on the master protocol design have been published, but their definitions of these such trials, including basket, umbrella, and platform trials, were not consistent. Concurrently, the acceleration of the development of new statistical designs for master protocol trials has been underway. This article provides an overview of recent reviews for master protocols, including their statistical design methodologies in Oncology. We also introduce several examples of previous and on-going master protocol trials along with their classifications by some recent studies. Keywords: Master protocol, Basket, Umbrella, Platform, Bayesian adaptive methodhttp://www.sciencedirect.com/science/article/pii/S2451865418300565 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Akihiro Hirakawa Junichi Asano Hiroyuki Sato Satoshi Teramukai |
spellingShingle |
Akihiro Hirakawa Junichi Asano Hiroyuki Sato Satoshi Teramukai Master protocol trials in oncology: Review and new trial designs Contemporary Clinical Trials Communications |
author_facet |
Akihiro Hirakawa Junichi Asano Hiroyuki Sato Satoshi Teramukai |
author_sort |
Akihiro Hirakawa |
title |
Master protocol trials in oncology: Review and new trial designs |
title_short |
Master protocol trials in oncology: Review and new trial designs |
title_full |
Master protocol trials in oncology: Review and new trial designs |
title_fullStr |
Master protocol trials in oncology: Review and new trial designs |
title_full_unstemmed |
Master protocol trials in oncology: Review and new trial designs |
title_sort |
master protocol trials in oncology: review and new trial designs |
publisher |
Elsevier |
series |
Contemporary Clinical Trials Communications |
issn |
2451-8654 |
publishDate |
2018-12-01 |
description |
In oncology, next generation sequencing and comprehensive genomic profiling have enabled the detailed classification of tumors using molecular biology. However, it is unrealistic to conduct phase I–III trials according to each sub-population based on patient molecular subtypes. Common protocols that assess the combination of several molecular markers and their targeted therapies by means of multiple sub-studies are required. These protocols are called “master protocols,” and are drawing attention as a next-generation clinical trial design. Recently, several reviews of clinical trials based on the master protocol design have been published, but their definitions of these such trials, including basket, umbrella, and platform trials, were not consistent. Concurrently, the acceleration of the development of new statistical designs for master protocol trials has been underway. This article provides an overview of recent reviews for master protocols, including their statistical design methodologies in Oncology. We also introduce several examples of previous and on-going master protocol trials along with their classifications by some recent studies. Keywords: Master protocol, Basket, Umbrella, Platform, Bayesian adaptive method |
url |
http://www.sciencedirect.com/science/article/pii/S2451865418300565 |
work_keys_str_mv |
AT akihirohirakawa masterprotocoltrialsinoncologyreviewandnewtrialdesigns AT junichiasano masterprotocoltrialsinoncologyreviewandnewtrialdesigns AT hiroyukisato masterprotocoltrialsinoncologyreviewandnewtrialdesigns AT satoshiteramukai masterprotocoltrialsinoncologyreviewandnewtrialdesigns |
_version_ |
1724818323908067328 |